140 related articles for article (PubMed ID: 15816543)
1. 1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors.
Zinser GM; Tribble E; Valrance M; Urben CM; Knutson JC; Mazess RB; Strugnell SA; Welsh J
Anticancer Res; 2005; 25(1A):235-41. PubMed ID: 15816543
[TBL] [Abstract][Full Text] [Related]
2. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
Wigington DP; Urben CM; Strugnell SA; Knutson JC
Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
[TBL] [Abstract][Full Text] [Related]
3. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
4. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer.
Nakagawa K; Kawaura A; Kato S; Takeda E; Okano T
Carcinogenesis; 2005 Feb; 26(2):429-40. PubMed ID: 15539405
[TBL] [Abstract][Full Text] [Related]
5. The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines.
Levy Y; Knutson JC; Bishop C; Shany S
Anticancer Res; 1998; 18(3A):1769-75. PubMed ID: 9673403
[TBL] [Abstract][Full Text] [Related]
6. Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells.
Wigington DP; Strugnell SA; Knutson JC
Anticancer Res; 2005; 25(3B):1909-17. PubMed ID: 16158925
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug.
Wang YR; Wigington DP; Strugnell SA; Knutson JC
Anticancer Res; 2005; 25(6B):4333-9. PubMed ID: 16309237
[TBL] [Abstract][Full Text] [Related]
8. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
9. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191).
Wietrzyk J; Pełczyńska M; Madej J; Dzimira S; Kuśnierczyk H; Kutner A; Szelejewski W; Opolski A
Steroids; 2004 Sep; 69(10):629-35. PubMed ID: 15465107
[TBL] [Abstract][Full Text] [Related]
11. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.
Yin Y; Ni J; Chen M; Guo Y; Yeh S
Clin Cancer Res; 2009 Jan; 15(1):190-200. PubMed ID: 19118046
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5.
Hussain-Hakimjee EA; Peng X; Mehta RR; Mehta RG
Carcinogenesis; 2006 Mar; 27(3):551-9. PubMed ID: 16195238
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model.
Wietrzyk J; Nevozhay D; Milczarek M; Filip B; Kutner A
Cancer Chemother Pharmacol; 2008 Oct; 62(5):787-97. PubMed ID: 18188568
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and systemic effect on calcium homeostasis of 1 alpha,24-dihydroxyvitamin D2 in rats. Comparison with 1 alpha,25-dihydroxyvitamin D2, calcitriol, and calcipotriol.
Knutson JC; LeVan LW; Valliere CR; Bishop CW
Biochem Pharmacol; 1997 Mar; 53(6):829-37. PubMed ID: 9113104
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative and calcemic actions of trans-decalin CD-ring analogs of 1,25-dihydroxyvitamin D3.
Eelen G; Verlinden L; Laureys J; Marcelis S; De Clercq P; Mathieu C; Bouillon R; Verstuyf A
Anticancer Res; 2009 Sep; 29(9):3579-84. PubMed ID: 19667151
[TBL] [Abstract][Full Text] [Related]
16. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution and activity studies of 1,24-dihydroxyvitamin D2, a metabolite of vitamin D2 with low calcemic activity in vivo.
Brown AJ; Ritter CS; Holliday LS; Knutson JC; Strugnell SA
Biochem Pharmacol; 2004 Oct; 68(7):1289-96. PubMed ID: 15345318
[TBL] [Abstract][Full Text] [Related]
18. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice.
Lin YJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):65-72. PubMed ID: 19343002
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5.
Peng X; Jhaveri P; Hussain-Hakimjee EA; Mehta RG
Carcinogenesis; 2007 May; 28(5):1000-7. PubMed ID: 17130524
[TBL] [Abstract][Full Text] [Related]
20. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.
Wu-Wong JR; Noonan W; Ma J; Dixon D; Nakane M; Bolin AL; Koch KA; Postl S; Morgan SJ; Reinhart GA
J Pharmacol Exp Ther; 2006 Jul; 318(1):90-8. PubMed ID: 16603671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]